Improvements in irritability with sertraline versus placebo: Findings from the EMBARC study.

ABSTRACT:

Background

This report seeks to evaluate improvements in symptoms of irritability with sertraline (a selective serotonin reuptake inhibitor antidepressant) versus placebo.

Methods

Participants of Establishing Moderators and Biosignatures of Antidepressant Response in Clinical Care (EMBARC) study who were randomized to 8 weeks of treatment with either sertraline or placebo and completed 5-item irritability domain of Concise Associated Symptom Tracking scale (CAST-IRR) at baseline were included (n = 292). Repeated measures mixed model analysis with CAST-IRR as the outcome variable and treatment arm-by-time interaction as the independent variable of interest evaluated whether changes in irritability with treatment differed between sertraline and placebo arms. A separate analysi

SUBMITTER: Jha MK 

PROVIDER: S-EPMC9764261 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature